Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; 1 of the 16 sources its claims cite were checked for support.
Abstract
Purpose: This study aimed to investigate changes in muscle mass and strength among older adults with type 2 diabetes who were treated with Semaglutide. Methods: This was a retrospective cohort study comparing elderly patients with type 2 diabetes receiving Semaglutide to a matched control group. Changes in muscle mass and function over 24 months were assessed. Muscle mass was measured using the appendicular skeletal muscle mass index (ASMI), while muscle function was evaluated through grip strength and gait speed measurements. Differences between the two groups and changes before and after treatment were analyzed using the t -test. Additionally, multivariable linear regression models were constructed to identify clinical predictors of accelerated muscle loss during Semaglutide treatment. Results: The study involved 220 patients treated with Semaglutide and 212 control subjects. The prevalence of sarcopenia among participants was 27.7%. Semaglutide treatment significantly reduced both body mass index and muscle mass compared to controls. Notably, divergent patterns emerged in functional measures. Grip strength initially improved but then declined in men, while it continued to decrease in women. Gait speed significantly reduced in both genders. Multivariable analysis identified Semaglutide dosage, baseline ASMI, and gait speed as independent predictors of muscle loss. Conclusion: The use of Semaglutide is associated with muscle loss and functional decline in older adults with type 2 diabetes, particularly at higher doses. This effect is especially significant in patients with sarcopenia. Consequently, it is crucial to assess the risks and benefits for each elderly patient individually and to implement appropriate monitoring and interventions. The potential for nutritional supplementation and targeted exercise regimens to counteract semaglutide-associated muscle decline merits systematic investigation. Keywords: older adults, type 2 diabetes, semaglutide, sarcopenia, muscle mass, mass strength
Overview
CoChat Summary
TL;DR
In older adults with type 2 diabetes, 24 months of semaglutide therapy was associated with greater reductions in BMI, muscle mass, handgrip strength, and gait speed than in matched controls. Higher semaglutide dose, lower baseline ASMI, and slower gait speed independently predicted greater muscle loss.
Key findings
- Among 220 semaglutide-treated patients and 212 matched controls, sarcopenia prevalence was 27.73%; at 24 months the semaglutide group had significantly lower BMI, ASMI, handgrip strength, and gait speed than controls (p<0.05).
- Cumulative ASMI loss by study end reached 0.39 kg/m² in females and 0.26 kg/m² in males; BMI fell continuously in the semaglutide group (p<0.001), and ASMI reductions became significant from month 12 onward.
- Handgrip strength in males transiently improved at 6 months then declined; females showed no significant 6-month change followed by significant deterioration. Gait speed showed statistically significant overall reductions in both genders.
- Multivariable linear regression identified semaglutide dosage, baseline ASMI, and gait speed as independent predictors of muscle loss, while handgrip strength lost statistical significance; the model had R²=0.337.
Methods
- Retrospective cohort study of patients ≥65 years with T2DM, BMI ≥24 kg/m², and no prior GLP-1RA or DPP-4 inhibitor use, initiating semaglutide at one hospital between January and December 2022; propensity score matching (1:1) used age, sex, baseline BMI, diabetes duration, and comorbidities.
- Participants were followed for 24 months with data at baseline, 6, 12, 18, and 24 months; muscle mass was measured by ASMI, and function by handgrip strength and 4-meter gait speed.
- Between-group and longitudinal comparisons used independent and paired t-tests, categorical variables used chi-square tests, and multivariable linear regression identified predictors of muscle loss.
Limitations
- Stated by the paper: relatively small sample size may limit generalizability; nutritional intake and physical activity patterns were not assessed; and the observational design prevents causal conclusions.
- Evident from the text: the study was conducted at a single hospital (“our hospital”), which may further limit external validity, and the retrospective source dataset lacked standardized lifestyle assessments.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
1 Valid · 0 Not valid · 13 Not checked · 37 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The use of Semaglutide is associated with muscle loss and functional decline in older adults with type 2 diabetes, particularly at higher doses.”
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Abstract > Conclusion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, at the 24-month follow-up, the Semaglutide-treated group exhibited significantly lower values for BMI, ASMI, handgrip strength, and gait speed compared to the control group (p< 0.05).”
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results
plainstates an associationn = 220 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
15 references still to check
A free account verifies the references that are still open.
- Not yet classified. 46
- It may state two separate claims as one. 3
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, higher semaglutide dosage (mg) emerged as an independent predictor of these adverse musculoskeletal changes. [60].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [60]
In the citing paper
“semaglutide use was associated with reductions in muscle mass and ASMI; while handgrip strength initially increased in men, it later declined in both sexes, and walking speed significantly decreased in both men and women.”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [60]
In the citing paper
“Observational data suggest that muscle wasting is not disproportionately accelerated by GLP-1RAs compared to other weight-loss interventions.”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results
“Hand grip strength (kg) | 18.97±3.25 | 26.20±3.24 | <0.001 | 28.99±2.60 | 35.94±3.48 | <0.001”
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Methods > Data Collection
“Sarcopenia diagnosis followed 2019 Asian Working Group for Sarcopenia (AWGS) criteria,7 requiring both low muscle mass (ASMI <7.0 kg/m² males, <5.7 kg/m² females) and reduced muscle strength (handgrip strength <28 kg males, <18 kg females).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Abstract > Results
“Grip strength initially improved but then declined in men, while it continued to decrease in women.”
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results > Longitudinal Changes in Anthropometric and Muscle Parameters
“Female participants, while showing no statistically significant change at 6 months, exhibited an upward trend that was subsequently followed by significant deterioration.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results
“Age (years) | 74.00±5.25 | 72.03±5.00 | 0.085 | 75.29±4.81 | 71.59±5.64 | <0.001”
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results
“Age (years) | 72.54±4.81 | 72.80±5.08 | 0.665 | 72.98±5.61 | 73.66±4.51 | 0.336”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Methods > Study Design and Participants
“Propensity score matching (1:1 ratio) was performed based on age, sex, baseline BMI, diabetes duration, and comorbidities.”
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results
“The analysis included 220 Semaglutide-treated patients and 212 matched controls.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results
“BMI (kg/m2) | 28.12±1.69 | 27.03±2.25 | 0.024 | 28.65±2.05 | 27.51±2.76 | 0.033”
§ Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study > Results
“BMI (kg/m2) | 27.28±2.18 | 27.80±1.95 | 0.065 | 27.68±2.57 | 27.88±2.23 | 0.545”
Citations
Cites
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“10 In older patients with T2DM, weight loss not only improves glycemic control but also reduces the risk of cardiovascular disease, 11 which is especially important in this population.”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“The weight-loss effects of Semaglutide, a long-acting GLP-1RA, are well-established, 9 and this was confirmed in our elderly cohort.”
Cruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“10 Thus, using Semaglutide in older patients with T2DM may exacerbate the development of sarcopenia due to negative energy balance.”
Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102
Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review
Li, C., Yu, K., Shyh‐Chang, N., Jiang, Z., Liu, T., Ma, S., Luo, L., Guang, L., Liang, K., Ma, W., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12901 · Cited by 626 · cited 1×
“15 Previous studies have confirmed that GLP-1RA treatment significantly reduces this pathological fat infiltration.”
Self-citationYao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Exercise for sarcopenia in older people: A systematic review and network meta‐analysis
Shen, Y., Shi, Q., Nong, K., Li, S., Yue, J., Huang, J., Dong, B., Beauchamp, M., & Hao, Q. (2023) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13225 · Cited by 464 · cited 1×
“18 Whether muscle loss can be prevented in Semaglutide users by increasing exercise participation needs further investigation.”
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · cited 1×
“Moreover, high doses of Semaglutide may more robustly suppress appetite and energy intake, 14 leading to exacerbated muscle mass loss.”
Cited by
Bansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 192
Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P., Guney, S., Aupetit, A., Aubourg, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70141 · Cited by 72
“21 These findings underscore the possibility of dose-related effects and differential responses according to age or baseline muscle status.”
Muscle loss and GLP-1R agonists use
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02611-2 · Cited by 31
“A cross-sectional study of older adults treated with semaglutide reported a prevalence of reduced muscle mass of 27.7%, reflecting the high base - line risk in this population rather than drug-specific effects [24].”
InfluentialProkopidis, K. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70355 · Cited by 29
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 28
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“Among these, the 24-month retrospective study by Ren et al. is particularly important because it directly examines semaglutide use in older adults with T2DM with an explicit focus on sarcopenia and provides relatively long-term outcomes [60 ].”
Chen, L., Zheng, J., Ye, B., Huang, Y., & Wang, Z. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112874 · Cited by 7
Iorra, F. D. Q., Jayakar, T., Yee, M. S., Thursz, M. R., Schaan, B. D., & Manousou, P. (2026) · Liver International · doi:10.1111/liv.70643 · Cited by 9
Beyond GLP‐1s: The blueprint for systemic therapeutics that will reshape aging and medicine
Kern, C. C., Jenkins, A., Reddy, D. N., Davis, B., Grzesiak, N., Faragher, R., Woods, T., Ayrton, J., & Stebbing, J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70312 · Cited by 3
GLP-1-derived therapies and risk of sarcopenia: myth or reality?
Scheen, A. J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2640980 · Cited by 5
Mogna-Peláez, P., & Guasch‐Ferré, M. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101684 · Cited by 4
“These methods provide objective, long-term data on lean mass changes that weight-based outcomes alone cannot reflect [17,26].”
InfluentialChen, Y., Qu, Y., Kong, S., Wang, T., Liu, Z., Ren, H., Ma, K., Zhao, T., Wang, H. W., & Wang, M. (2026) · Medicine · doi:10.1097/md.0000000000049398 · Cited by 5
Chen, H.-Y., Wu, J., Chu, Y.-H., Chen, T.-W., & Huang, C. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08134-y · Cited by 5
Hierholzer, J. D., Benson, H., Ewida, H. A., & Ahmed, M. S. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168172 · Cited by 4
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
“141,194,195 For example, in overweight or obese elderly patients with type 2 diabetes, a 24-week liraglutide treatment maintained skeletal muscle index (SMI), reduced fat mass, and prevented SP onset.”
Ray, S. D., He, L. L., Rottersmann, S., Hand, C., Leo, M. D., Chunilall, A., Gray, I. G., Siu, N. T., Jong, S., Sirois, N., et al. (2026) · Diabetology · doi:10.3390/diabetology7090176 · Cited by 3
TAS1R3 Regulates GTPase Signaling in Human Skeletal Muscle Cells for Glucose Uptake
Hoolachan, J. M., Balakrishnan, R., Merz, K. E., Thurmond, D. C., & Veluthakal, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010103 · Cited by 2
“Weight management is a key intervention for mitigating insulin resistance and T2D, and the widely used glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an elevated risk of sarcopenia [14–17].”
Body Contouring Surgery in the Era of GLP–1 Receptor Agonists: A Narrative Review
Duque, M. A. S., & Galvis, A. E. G. (2026) · Indian Journal of Plastic Surgery · doi:10.1055/s-0046-1824526 · Cited by 1
Shrestha, R., Kovacevich, A., Yerneni, H., Shroff, P., & Sajatovic, M. (2026) · Psychiatric Annals · doi:10.3928/00485713-20260701-01 · Cited by 1
Kern, C. C., Woods, T., & Siew, K. (2026) · Experimental Physiology · doi:10.1113/ep092652 · Cited by 1
“General sarcopenia and lipodystrophy are also risks, alongside knock-on consequences such as rapid fat loss stressing the retina to induce macular degeneration (Ren et al., 2025; Shor et al., 2025).”
Prokopidis, K., Cacciatore, S., Anton, S. D., & Batsis, J. A. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03750-w · Cited by 4
Semaglutide: Scoping Review with ☸️SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsara45190890
Glucagon like Peptide-1 (GLP‑1) receptor agonists: There is no such thing as a free lunch
Hendrickse, P. W., Hayes, L. D., & Gaffney, C. J. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.026
Labate, A. M., Moretti, L., & Villari, P. (2026) · Endocrines · doi:10.3390/endocrines7010008
“Conversely, a 24-month retrospective cohort study by Ren et al. described reductions in muscle mass and functional measures in older adults treated with semaglutide [12,23], underscoring the importance of individualized risk-benefit assessment and monitoring in frail patients.”
АГОНІСТИ РЕЦЕПТОРІВ ГПП-1: ПЕРЕВАГИ ТА РИЗИКИ
Doroshkevych, I. O., Vlasenkо, М. V., Жамба, А. О., Semenenko, S., & Palamarchuk, A. V. (2026) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2026.2.05
Fouad, Y. M., AlNaamani, K. M., Alawadi, F., Hassani, A. A., Alkhalidi, N. M. F., Hotayt, B., Abaalkhail, F. A., Rouabhia, S., Abdulla, M., Altarrah, M. Y., et al. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2698115
“Another key concern is the potential worsening of sarcopenia in patients treated with semaglutide, characterized by the loss of skeletal muscle mass, quality, and strength, which is a significant complication in patients with cirrhosis and may be exacerbated by rapid weight loss [21,22].”
Joshi, S., Misra, A., Mithal, A., Saboo, B., Seshadri, K., Chowdhury, S., Bantwal, G., Sethi, B. K., Kesavadev, J., Bhattacharya, A. D., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100296
“2025), the semaglutide-treated group reported significantly lower BMI, appendicular skeletal muscle mass index, gait speed, and handgrip strength [48].”
Ahmed, A. K. K., Rodini, S., Alrubyea, F., & Akl, M. M. (2026) · Problems of Endocrinology · doi:10.14341/probl13660
“…with significant reductions in appendicular skeletal muscle mass index (ASMI; potentially 7–12%), grip strength (12– 18%), and gait speed (0.15–0.25 m/s), with sarcopenia prevalence at 27.7% and dosage as an independent predictor, suggesting mTORC1 suppression and catabolic predominance [26].”
InfluentialKim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 3
“Although the retrospective design precludes causal inference, these findings reinforce the importance of individualized assessment in vulnerable populations [12].”
Jagasia, K., Pfeiffer, A. M., & Vitale, K. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100083 · Cited by 2
“The critical implications of decreased grip strength while on GLP-1-RA highlight the necessity for future studies to examine older adult populations to validate the findings from Ren et al., 2025 [51].”
InfluentialASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome
Bansal, N., Bjornstad, P., Bress, A. P., Chang, T. I., Cheng, X. S., Estrella, M. M., Go, A. S., Mottl, A. K., Navaneethan, S. D., Neuen, B. L., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001231 · Cited by 3
The longevity dividend: Why governments and markets must catch up
Grzesiak, N., Kern‐Libera, S., Faragher, R., Jenkins, A., Coughlan, G. D., Bailey, D. M., & Kern, C. C. (2026) · Experimental Physiology · doi:10.1113/ep092866
“…of mechanistic understanding, side effects temper the overall benefits for GLP-1s in particular, and as recent research demonstrates, there is potential for complications in the form of accelerated ageing phenotypes, from macular degeneration to sarcopenia (Ren et al., 2025; Shor et al., 2025).”
Mironova, M., Ratziu, V., Rinella, M. E., Bansal, M. B., Noureddin, M., Alkhouri, N., Anstee, Q. M., Newsome, P. N., Schattenberg, J. M., Sanyal, A. J., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-340031
Glucagon-like peptide-1 receptor agonists and cognitive function: beyond the metabolic effects
Pοlyzos, S. A., Doulberis, M., Zervogiannis, N., Batakoias, C.-A., & Kountouras, J. (2026) · HORMONES · doi:10.1007/s42000-026-00827-7
Mokrzecki, S., Mamach, A., Bełc, E., Brzezińska, K., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Król, M., Straszewska, A., Woźniak, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6230
Knapik, J., Fic, W., & Polak-Szczybyło, E. (2026) · Nutrients · doi:10.3390/nu18193247
“Moreover, one study in older adults reported lower handgrip strength and gait speed after 24 months of treatment [65].”
Functional Implications of GLP-1RA Use Beyond Obesity in Aging Adults
Mascone, S. E., Prior, S. J., & Addison, O. R. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00467-0
“Further, greater muscle mass loss with GLP-1RA usage was associated with higher GLP-1RA dosage and lower baseline handgrip strength and functional status [27].”
InfluentialZhang, J., Zhai, X., Sha, S., & Zhang, L. (2026) · Drugs · doi:10.1007/s40265-026-02408-9
Machado, L. G., Schmidt, P. H. S., Petroski, G. T., Costa, G. L. L., Ribeiro, L., da Cruz, J. V. R., Canto, G. D. L., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71432 · Cited by 2
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies
Kounatidis, D. C., Vallianou, N. G., Kouveletsou, M., Kontrafouri, P., Stamatopoulos, V., Rebelos, E., Diakoumopoulou, E., & Dalamaga, Μ. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00770-z
“Interestingly, research supports that GLP-1RA therapy may favor the development of neuromuscular junction dysfunction in older patients with diabetes [169 – 171].”
Koufakis, T., Tentolouris, A., Manthou, E., Teperikidis, L., Mylonas, A., Kotsa, K., & Doumas, M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03829-4
Kaşkal, M., Alam, U., & Lip, G. Y. H. (2026) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001262
Nutritional Impairment and Muscle Health in MASLD: The Potential Role of Eating Behaviors
Armașu, I., Ungureanu, M.-C., Gheorghe, L., Botnariu, G., Florescu, A.-F., Matei, A., Jari, I., Rusu, R. E., Cojocaru, E., Vasiliu, I., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218306
Metadata
- Authors
- Ren, Q., Zhi, L., & Liu, H.
- Corresponding author
- Ren, Qingjuan
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2025-07
- Volume
- Volume 19
- Pages
- 5645-5652
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC12235021
- OpenAlex
- W4411931568
- Cited by
- 44
- References
- 19
- Citations by year
- 2026: 37 · 2025: 7
- FWCI
- 28.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- semaglutide, sarcopenia, type 2 diabetes, older adults, muscle mass, muscle strength, grip strength, walking speed, appendicular skeletal muscle mass index, muscle mass loss, GLP-1 receptor agonists, body mass index
- MeSH terms
- Semaglutide, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Cohort Studies, Muscle, Skeletal, Hand Strength, Glucagon-Like Peptide 1, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.